Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events

Item

http://www.wikidata.org/entity/Q37471067

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events

@en

Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events.

@nl

type

Item

label

Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events

@en

Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events.

@nl

prefLabel

Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events

@en

Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events.

@nl

P1476

Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events

@en

P2093

Bruce Green

http://www.w3.org/2001/XMLSchema#string

John J Atherton

http://www.w3.org/2001/XMLSchema#string

Michael A Barras

http://www.w3.org/2001/XMLSchema#string

Stephen B Duffull

http://www.w3.org/2001/XMLSchema#string

P2860

A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients

Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction

Prediction of creatinine clearance from serum creatinine

Ways to fit a PK model with some data below the quantification limit.

Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials.

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.

Development of a dosing strategy for enoxaparin in obese patients.

P304

700-711

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.2009.03518.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38092876

http://www.w3.org/2001/XMLSchema#string

P698

19916994

http://www.w3.org/2001/XMLSchema#string

P932

2791976

http://www.w3.org/2001/XMLSchema#string